Ambalal Sarabhai Enterprises Ltd.
Snapshot View

23.30 +0.10 ▲0.4%

07 February 2023, 04:01:00 PM
Volume: 42,579

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.ase.life
Market Cap 177.02 Cr.
Enterprise Value(EV) 183.52 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) 1.79 Trailing Twelve Months Ending 2022-09
Price-Earning Ratio (PE) 13.04 Trailing Twelve Months Ending 2022-09
Industry PE 32.80 Trailing Twelve Months Ending 2022-09
Book Value / Share 15.99 Trailing Twelve Months Ending 2022-09
Price to Book Value 1.46 Calculated using Price: 23.30
Dividend Yield 0.00 Period Ending 2022-03
No. of Shares Subscribed 7.66 Cr. 76,633,296 Shares
FaceValue 10
Company Profile
Ambalal Sarabhai Enterprises is a Baroda-based pharmaceutical manufacturing company which was incorporated in 1977. It is one of the company belonging to the Sarabhai Group. The Group's principal activity is manufacture and marketing of pharmaceutical products and bulk drugs. The company's plants are located at Vadodara and Ahmedabad.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
+0.43%
1 Week
-3.72%
1 Month
-13.70%
3 Month
-21.81%
6 Month
-22.72%
1 Year
-39.32%
2 Year
+9.13%
5 Year
+94.33%
10 Year
+513.16%
9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) -256.13 328.25 -57.92 4.20 7.01 40.95 49.47 48.74
Return on Capital Employed (%) -17.91 10.08 107.14 -11.94 16.34 13.17 27.14 40.28 45.53
Return on Assets (%) -9.58 -3.51 25.83 -10.30 0.62 0.99 7.84 15.02 21.57

Balance Sheet View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds -2 -9 39 25 27 31 45 74 120 123
Non Curr. Liab. 59 15 13 6 11 9 5 5 5 9
Curr. Liab. 155 163 153 124 155 171 133 129 105 101
Minority Int. 0 0 0 0 0
Equity & Liab. 211 169 204 155 193 211 183 208 230 233
Non Curr. Assets 144 100 92 82 80 95 79 87 110 115
Curr. Assets 67 68 112 73 114 116 104 121 120 117
Misc. Exp. not W/O
Total Assets 211 169 204 155 193 211 183 208 230 233

Profit Loss View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09 Rs. Cr. TTM
Net Sales 105 125 132 134 125 152 134 164 197 188
Other Income 3 13 95 6 25 5 24 31 42 14
Total Income 108 137 227 140 150 157 158 194 239 202
Total Expenditure -113 -129 -145 -145 -137 -146 -135 -165 -172 -177
PBIDT -6 9 82 -5 13 11 22 29 67 25
Interest -11 -10 -4 -5 -3 -3 -4 -3 -2 -2
Depreciation -3 -5 -17 -4 -2 -2 -3 -2 -2 -2
Taxation -1 -1 -14 -5 -7 -4 -1 -3 -7 -5
Exceptional Items -15
PAT -20 -7 48 -19 1 2 15 29 47 16
Minority Interest
Share Associate 0 0 2 -1 -2
Other Related Items
Consolidated Net Profit -20 -7 48 -18 1 4 14 29 47 14
Adjusted EPS -3 -1 6 -2 0 1 2 4 6 2

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. -3 11 -8 -75 5 -7 19 -7 -2 11
Cash Fr. Inv. 0 -1 10 80 -3 18 -9 17 10 5
Cash Fr. Finan. 3 -8 -1 -3 -6 -2 -6 -14 -6 -19
Net Change -1 2 1 2 -4 8 3 -4 2 -3
Cash & Cash Eqvt 6 8 8 10 5 14 17 13 15 12

Shareholding Pattern View Details >>

9 Qtrs 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%)
Promoter 30.76 30.76 30.76 30.76 30.76 30.76 30.76 30.76 30.77
Public 69.24 69.24 69.24 69.24 69.24 69.24 69.24 69.24 69.23
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details >>

Sat, 04 Feb 2023
Board Meeting Intimation for Approval Of Un-Audited Financial Results For The Quarter And Nine Months Ended December 31 2022
AMBALAL SARABHAI ENTERPRISES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2023 inter alia to consider and approve the Un-audited Financial Results (Standalone & Consolidated) of the Company for the Quarter and nine months ended December 31 2022 and any other matter as the Board of Directors of the Company may decide during the course of the Meeting. This is in pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015.This is for your information and records.
Fri, 13 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 we enclose herewith a confirmation certificate received from MCS Share Transfer Agent Limited the Registrar and Transfer Agent of the Company for the period ended on 31st December 2022. You are requested to take the above on record.
Fri, 13 Jan 2023
Board Meeting Outcome for Outcome Of The Board Meeting Held On 13.01.2023
We wish to inform you that the Board of Directors of the Company at their meeting held on 13.01.2023 has approved the Scheme of Arrangement in the nature of Demerger and vesting of the Oncology and Profertility Division of Sarabhai Chemicals (India) Private Limited (SCIPL) into Asence Pharma Private Limited (APPL) subject to the approval of NCLT Shareholders of respective Companies Creditors and other regulatory bodies as applicable under Sections 230 to 232 of the Companies Act 2013 and other applicable provisions of the Companies Act 2013.Disclosure in terms of Regulation 30 of the SEBI (LODR) Regulations 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9 2015 is attached as Annexure I.You are requested to take the same on your record.

Technical Scans View Details >>

Tue, 07 Feb 2023
High Delivery Percentage High Delivery Percentage
Opening at High Opening at High
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
Close Below Last Month Low Close Below Last Month Low
High Decrease in 1 Month High Decrease in 1 Month

Related Stocks View Details >>

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 241,289.12 1,005.65 -1.7%
Cipla Ltd. 83,256.90 1,031.50 +0.2%
Dr. Reddy's Laboratories Ltd. 73,968.14 4,441.90 +2.1%
Divi's Laboratories Ltd. 72,982.62 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. 62,135.10 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. 51,898.92 1,533.45 -0.4%
Zydus Lifesciences Ltd. 48,525.07 479.40 +2.0%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 57.29 1,005.65 -1.7%
Cipla Ltd. Consolidated 2022-12 31.56 1,031.50 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 20.30 4,441.90 +2.1%
Divi's Laboratories Ltd. Consolidated 2022-12 30.45 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 74.00 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 62.45 1,533.45 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-12 23.54 479.40 +2.0%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 4.36 1,005.65 -1.7%
Cipla Ltd. Consolidated 2022-12 3.67 1,031.50 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 3.36 4,441.90 +2.1%
Divi's Laboratories Ltd. Consolidated 2022-12 5.87 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 10.38 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 8.14 1,533.45 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-12 2.81 479.40 +2.0%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 1,005.65 -1.7%
Cipla Ltd. Consolidated 2022-03 0.04 1,031.50 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,441.90 +2.1%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,533.45 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-03 0.25 479.40 +2.0%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,005.65 -1.7%
Cipla Ltd. Consolidated 2022-03 13.10 1,031.50 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,441.90 +2.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,533.45 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 479.40 +2.0%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,005.65 -1.7%
Cipla Ltd. Consolidated 2022-03 13.10 1,031.50 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,441.90 +2.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,533.45 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 479.40 +2.0%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,005.65 -1.7%
Cipla Ltd. Consolidated 2022-03 21,763.34 1,031.50 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,441.90 +2.1%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,533.45 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-03 15,265.20 479.40 +2.0%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,005.65 -1.7%
Cipla Ltd. Consolidated 2022-03 2,559.47 1,031.50 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,441.90 +2.1%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,533.45 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-03 2,326.40 479.40 +2.0%

FAQ's On Ambalal Sarabhai Enterprises Ltd.

What is Ambalal Sarabhai Ent share price?

Can I buy Ambalal Sarabhai Ent shares now?

What is the Market Cap of Ambalal Sarabhai Ent?

What are the key metrics to analyse Ambalal Sarabhai Ent?

What is the 52 Week High and Low of Ambalal Sarabhai Ent?

What is the trend of Ambalal Sarabhai Ent share price?